Organon & Co. (OGN)

USD 9.59

(1.48%)

EBITDA Summary of Organon & Co.

  • Organon & Co.'s latest annual EBITDA in 2023 was 1.43 Billion USD , down -8.11% from previous year.
  • Organon & Co.'s latest quarterly EBITDA in 2024 Q1 was 479 Million USD , up 28.07% from previous quarter.
  • Organon & Co. reported an annual EBITDA of 1.69 Billion USD in 2022, down -6.84% from previous year.
  • Organon & Co. reported an annual EBITDA of 1.81 Billion USD in 2021, down -39.65% from previous year.
  • Organon & Co. reported a quarterly EBITDA of 452 Million USD for 2024 Q2, down -9.81% from previous quarter.
  • Organon & Co. reported a quarterly EBITDA of 479 Million USD for 2024 Q1, up 28.07% from previous quarter.

Annual EBITDA Chart of Organon & Co. (2023 - 2017)

Historical Annual EBITDA of Organon & Co. (2023 - 2017)

Year EBITDA EBITDA Growth
2023 1.43 Billion USD -8.11%
2022 1.69 Billion USD -6.84%
2021 1.81 Billion USD -39.65%
2020 2.98 Billion USD -28.09%
2019 4.18 Billion USD -7.07%
2018 4.37 Billion USD -14.24%
2017 5.07 Billion USD 0.0%

Peer EBITDA Comparison of Organon & Co.

Name EBITDA EBITDA Difference
AbbVie Inc. 26.35 Billion USD 94.552%
Bristol-Myers Squibb Company 19.41 Billion USD 92.604%
Bristol-Myers Squibb Company Ce 19.41 Billion USD 92.604%
Johnson & Johnson 23.72 Billion USD 93.947%
Eli Lilly and Company 8.56 Billion USD 83.24%
Merck & Co., Inc. 6.9 Billion USD 79.209%
Novartis AG 18.28 Billion USD 92.147%
Pfizer Inc. 9.55 Billion USD 84.974%